PMID- 24595507
OWN - NLM
STAT- MEDLINE
DCOM- 20150910
LR  - 20220310
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 231
IP  - 18
DP  - 2014 Sep
TI  - Association between the brain-derived neurotrophic factor Val66Met polymorphism 
      and therapeutic response to olanzapine in schizophrenia patients.
PG  - 3757-64
LID - 10.1007/s00213-014-3515-4 [doi]
AB  - RATIONALE: Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays 
      a major role in neurogenesis and neuroplasticity, and in the modulation of 
      several neurotransmitter systems including the dopaminergic system. There are 
      mixed reports about the association between the BDNF Val66Met polymorphism, 
      schizophrenia, and treatment response to antipsychotic drugs. OBJECTIVES: The 
      present study evaluated the association of the BDNF Val66Met polymorphism with 
      treatment response to atypical antipsychotic olanzapine in schizophrenia and the 
      possible predictive value of the BDNF Val66Met genotype status in treatment 
      response to antipsychotic medication. METHODS: The study included 590 ethnically 
      homogenous Caucasian patients with schizophrenia (diagnosed using the SCID), 
      40.2 +/- 12.0 years old, treated with olanzapine monotherapy (10-20 mg/day), or 
      with other antipsychotics such as risperidone (3-6 mg/day), clozapine (100-500 
      mg/day), haloperidol (3-115 mg/day), fluphenazine (4-25 mg/day), and quetiapine 
      (50-800 mg/day). Patients were subdivided into responders and non-responders 
      according to a 50 % reduction in the Positive and Negative Syndrome Scale (PANSS) 
      total and subscale scores after 8 weeks of treatment. RESULTS: The results, 
      corrected for possible effects of gender and age, showed a significant 
      association between the BDNF Val66Met polymorphism and treatment response to 
      olanzapine in patients. The Val/Val genotype was observed more frequently in 
      treatment responders to olanzapine, and this genotype was associated with an 
      improvement in clinical symptoms. CONCLUSIONS: Our results suggest that BDNF 
      Val66Met variants might influence the response to 8 weeks of monotherapy with 
      olanzapine, in a relatively large sample of patients with schizophrenia.
FAU - Nikolac Perkovic, Matea
AU  - Nikolac Perkovic M
AD  - Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, 
      Zagreb, Croatia.
FAU - Nedic Erjavec, Gordana
AU  - Nedic Erjavec G
FAU - Zivkovic, Maja
AU  - Zivkovic M
FAU - Sagud, Marina
AU  - Sagud M
FAU - Uzun, Suzana
AU  - Uzun S
FAU - Mihaljevic-Peles, Alma
AU  - Mihaljevic-Peles A
FAU - Kozumplik, Oliver
AU  - Kozumplik O
FAU - Muck-Seler, Dorotea
AU  - Muck-Seler D
FAU - Pivac, Nela
AU  - Pivac N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140305
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 12794-10-4 (Benzodiazepines)
RN  - J60AR2IKIC (Clozapine)
RN  - J6292F8L3D (Haloperidol)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Benzodiazepines/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Clozapine/therapeutic use
MH  - Female
MH  - Genetic Association Studies
MH  - Genotype
MH  - Haloperidol/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Pharmacogenetics
MH  - *Polymorphism, Single Nucleotide
MH  - Predictive Value of Tests
MH  - Risperidone/therapeutic use
MH  - Schizophrenia/*drug therapy/*genetics
MH  - Treatment Outcome
EDAT- 2014/03/07 06:00
MHDA- 2015/09/12 06:00
CRDT- 2014/03/06 06:00
PHST- 2013/12/27 00:00 [received]
PHST- 2014/02/15 00:00 [accepted]
PHST- 2014/03/06 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 10.1007/s00213-014-3515-4 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2014 Sep;231(18):3757-64. doi: 
      10.1007/s00213-014-3515-4. Epub 2014 Mar 5.